Modulating the Amyloidogenesis of α-Synuclein

E-ISSN： 1875-6190|14|3|226-237

ISSN： 1570-159X

Source： Current Neuropharmacology, Vol.14, Iss.3, 2016-04, pp. : 226-237

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Interaction of Prolyl Oligopeptidase with -Synuclein

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 10, Iss. 3, 2011-05 ,pp. : 349-354

Bentham Science Publishers

Access to resources Recommend Favorite

A Brief Overview of Tyrosine Hydroxylase and -Synuclein in the Parkinsonian Brain

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 11, Iss. 4, 2012-06 ,pp. : 456-462

Bentham Science Publishers

Access to resources Recommend Favorite

Commentary 1 (Research Highlights: Parkinson's Disease and -Synuclein: Passing it on)

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 12, Iss. 1, 2013-02 ,pp. : 2-2

Bentham Science Publishers

Access to resources Recommend Favorite

-Synuclein- and MPTP-Generated Rodent Models of Parkinson's Disease and the Study of Extracellular Striatal Dopamine Dynamics: A Microdialysis Approach

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 9, Iss. 4, 2010-08 ,pp. : 482-490

Bentham Science Publishers

Access to resources Recommend Favorite

Curcumin-glucoside, A Novel Synthetic Derivative of Curcumin, Inhibits -Synuclein Oligomer Formation: Relevance to Parkinson's Disease

Current Pharmaceutical Design, Vol. 18, Iss. 1, 2012-01 ,pp. : 76-84

Bentham Science Publishers

Access to resources Recommend Favorite